Introduction: Diarrhea is the primary dose-limiting side effect of capecitabine(Cap) hindering its clinical application, but the mechanism is unclear. Clarifying this mechanism may enhance the patient compliance and improve the treatment outcome.
Objectives: To assess if the endogenous metabolic profile could prodict the diarrhea induced by Cap and explore and validate underlying mechanisms.
Methods: Untargeted and targeted bile acids(BAs) metabolomics were performed to analyzed the metabolic profile of baseline samples from colorectal cancer(CRC) patients and the association with the diarrhea induced by Cap was assessed. The toxicity of BAs and Cap and its metabolites alone or their combinations to the human normal intestinal epithelial cell(HIEC) was assessed, and the key genes that mediated the BAs-enhanced toxicity of Cap were discovered by RNA-seq and then validated. A mouse model with high exposure levels of BAs was constructed and then treated with Cap to verify the Cap-induced diarrhea enhanced by BAs.
Results: The baseline endogenous metabolic profile showed obviously difference between diarrhea and non-diarrhea CRC patients, and the differential metabolites mainly enriched in BAs metabolism; the deoxycholic acid(DCA) and lithocholic acid(LCA) were selected to be the key BAs that enhanced the toxicity of Cap metabolite 5-FU to the HIEC cell; the DCA and LCA could inhibit the Wnt/β-catenin signaling pathway, which then suppressed the P-glycoprotein and increased the exposure level of 5-FU in the HIEC cell. The results of animal experiment verified that the excessive DCA and LCA could aggravate the Cap-induced diarrhea through inhibiting Wnt/β-catenin-P-glycoprotein pathway.
Conclusions: The disordered BAs metabolic profile showed close relationship with diarrhea induced by Cap, and excessive DCA and LCA were proved to be the key BAs, which could aggravate the Cap-induced diarrhea through inhibiting Wnt/β-catenin-P-glycoprotein pathway.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jare.2024.07.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chemotherapy-induced diarrhea (CID) is a common and harmful side effect of chemotherapy, greatly impacting patients' quality of life and potentially compromising their chances of survival. Disruption of the balance in intestinal microbiota and compromised integrity of the intestinal barrier are key factors contributing to CID caused by mucositis. This paper investigated the mechanism through which intestinal microbiota activate Toll-like receptors and STING pathways to mediate intestinal mucosal inflammation resulting from immune responses in the gut, uncovering a novel mechanism of intestinal microbiota in chemotherapy-induced diarrhea, and suggesting innovative approaches for the prevention and management of CID.
View Article and Find Full Text PDFSupplemental glucose oxidase as an antibiotic substitute alleviates diarrhea and improves intestinal health in weaned piglets.
Vet Q
December 2025
Guangdong Provincial Key Laboratory of Animal Nutrition Control, College of Animal Science, South China Agricultural University, Guangzhou, China.
Weaning stress-induced diarrhea is a serious issue in pig production. This study aimed to evaluate the potential of glucose oxidase (GOD) as an antibiotic substitute to alleviate diarrhea and improve gut health in weaned piglets. According to a randomized complete block design, 250 piglets weaned around 21 d of age were allocated into 5 groups (5 replicates/group), which received a basal diet without or with supplemental 200 mg/kg antibiotic, 500, 1000 and 2000 U/kg GOD, respectively.
View Article and Find Full Text PDFMechanism of podophyllotoxin-induced ovarian toxicity via the AMPK/TSC1/mTOR/ULK1 axis in rats on the basis of toxicological evidence chain (TEC) concept.
Ecotoxicol Environ Saf
December 2024
Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China. Electronic address:
Article Synopsis
- Podophyllotoxin has potential clinical benefits, such as anticancer effects, but its toxicity limits its use in medicine.
- The research involved creating a rat model to study how podophyllotoxin damages ovaries, revealing symptoms like diarrhea and bruising, alongside significant biochemical and pathological changes.
- The study found that podophyllotoxin's toxicity is linked to alterations in autophagy, specifically through the AMPK/TSC1/mTOR/ULK1 signaling pathway, providing new insights for its clinical application.
Oxyresveratrol Alleviates Irinotecan-Induced Diarrhea and Enhances Antitumor Effects in Colorectal Cancer.
Drug Des Devel Ther
January 2025
West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Objective: To investigate whether oxyresveratrol (OXY) can alleviate irinotecan (CPT-11)-induced intestinal toxicity and whether the combination of these two drugs can enhance the inhibition of colorectal cancer cells.
Methods: The CCK-8 assay was used to assess the inhibitory effects of OXY and CPT-11, both as monotherapies and in combination, on the proliferation of colorectal cancer cell lines HCT116 and SW620. Mice were grouped (8/mice/group) into: control, CPT-11, low-dose OXY+CPT-11, high-dose OXY+CPT-11.
A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System.
Front Pharmacol
December 2024
Department of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Aims: The primary objective of this study was to closely monitor and identify adverse events (AEs) associated with Sorafenib, a pharmacological therapeutic agent used to treat hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. The ultimate goal was to optimize patient safety and provide evidence-based guidance for the appropriate use of this drug.
Methods: Reports from the FDA Adverse Event Reporting System (FAERS) database were comprehensively collected and analyzed, covering the first quarter of 2004 to the first quarter of 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!